Breaking News Instant updates and real-time market news.

KR

Kroger

$21.56

1.03 (5.02%)

, CL

Colgate-Palmolive

$74.35

1.45 (1.99%)

09:55
10/11/17
10/11
09:55
10/11/17
09:55

Early notable gainers among liquid option names on October 11th

Notable gainers among liquid option names this morning include Kroger (KR) $21.73 +1.20, Colgate Palmolive (CL) $74.73 +1.84, Range Resources (RRC) $20.03 +0.42, PayPal (PYPL) $67.31 +1.27, and Johnson & Johnson (JNJ) $136.09 +2.14.

KR

Kroger

$21.56

1.03 (5.02%)

CL

Colgate-Palmolive

$74.35

1.45 (1.99%)

RRC

Range Resources

$20.18

0.57 (2.91%)

PYPL

PayPal

$66.04

-0.19 (-0.29%)

JNJ

Johnson & Johnson

$135.85

1.945 (1.45%)

  • 11

    Oct

  • 11

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 27

    Oct

  • 06

    Nov

  • 15

    Nov

  • 16

    Nov

  • 29

    Nov

  • 30

    Nov

KR Kroger
$21.56

1.03 (5.02%)

09/19/17
PIPR
09/19/17
DOWNGRADE
Target $72
PIPR
Neutral
Kellogg downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Michael Lavery downgraded Kellogg (K) to Neutral saying cereal could be at risk from shrinking center store space. Recent comments by Kroger (KR) and Campbell Soup (CPB) indicate retailer pushback is a real threat to packaged food suppliers, Lavery tells investors in a research note. He adds that scanner data suggests Kellogg's sales trends are worse than expected in both snacks and cereal. The analyst dropped his price target for Kellogg to $72 from $78.
10/04/17
BERN
10/04/17
NO CHANGE
BERN
Ahold Delhaize, Kroger deal would make sense, says Bernstein
Bernstein analyst Bruno Monteyne notes that Bloomberg is reporting speculation on Twitter (TWTR) that Ahold Delhaize (ADRNY) has hired advisors to study a possible $32/share Kroger (KR) bid. The analyst believes a merger makes sense both strategically and financially, but deal structure seems off - merger of equals rather than bid - and timing a bit too fast.
09/12/17
09/12/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Comerica (CMA) upgraded to Overweight from Neutral at Piper Jaffray with analyst Brett Rabatin saying the bank's mid-quarter update is better than expected. 2. Alcoa (AA) upgraded to Buy from Hold at Deutsche Bank with analyst Jorge Beristain basing the upgrade on the firm's commodity team raising its 2018 aluminum price forecast by 12% to $2,072 per ton. 3. Kroger (KR) upgraded to Buy from Hold at Pivotal Research with analyst Ajay Jain saying continued weakness in investor sentiment following Kroger's latest results presents a near-term buying opportunity. 4. Comcast (CMCSA) upgraded to Buy from Neutral at MoffettNathanson with analyst Craig Moffett saying Comcast shares cheap following management comments on third quarter subscriber loses and the resulting stock selloff is overdone. 5. Inovalon (INOV) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Ricky Goldwasser saying that the company's presentation at the firm's healthcare conference provided a line of sight to organic earnings acceleration in the second half of the year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/17
PIVT
09/12/17
UPGRADE
PIVT
Buy
Kroger upgraded to Buy from Hold at Pivotal Research
Pivotal Research analyst Ajay Jain upgraded Kroger to Buy with an unchanged price target of $25. The supermarket owner closed yesterday up 28c to $21.34. Continued weakness in investor sentiment following Kroger's latest results presents a near-term buying opportunity, Jain tells investors in a research note. The analyst, while admitting it is difficult to call an absolutely bottom amid an increasingly competitive operating environment, says the stock's risk/reward is "finally improving."
CL Colgate-Palmolive
$74.35

1.45 (1.99%)

09/25/17
09/25/17
UPGRADE
Target $84

Overweight
Colgate-Palmolive upgraded to Overweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Dara Mohsenian upgraded Colgate-Palmolive to Overweight from Equal Weight and called the stock his top household products pick, saying he sees the company returning to above-peer growth beginning in Q4 and he thinks investors will soon "flock back" to emerging-market-centric names, like Colgate. The analyst, who thinks Colgate's valuation is attractive, also believes the company has multiple plausible strategic partners, unlike most peers. Mohsenian raised his price target on the stock to $84 from $75.
10/11/17
RHCO
10/11/17
UPGRADE
RHCO
Buy
Colgate-Palmolive upgraded to Buy from Hold at SunTrust
09/25/17
MSCO
09/25/17
UPGRADE
MSCO
Overweight
Colgate-Palmolive upgraded to Overweight from Equal Weight at Morgan Stanley
10/11/17
RHCO
10/11/17
UPGRADE
Target $85
RHCO
Buy
Colgate-Palmolive upgraded to Buy at SunTrust
As previously noted, SunTrust analyst William Chappell upgraded Colgate-Palmolive to Buy from Hold and raised his price target on the stock to $85 from $65. Chappell says the recent three consecutive quarters of weak results is an "anomaly" given the company's long term track record of consistent mid-single-digit or higher organic growth. The analyst also points to reacceleration in the emerging market middle class growth and favorable foreign exchange conditions for the first time in years.
RRC Range Resources
$20.18

0.57 (2.91%)

08/29/17
JEFF
08/29/17
NO CHANGE
Target $25
JEFF
Buy
Jefferies cuts oil forecast, Exploration & Production price targets
Jefferies lowered its Brent estimate to $57 per barrel from $64 in 2018, to $60 from $67 in 2019, and to $65 from $70 in 2020. The market appears to be adequately supplied in the near term, but depleting proved developed reserves and shrinking spare capacity should support rising longer-term price assumption, analyst Michael Hsu tells investors in a research note. To reflect the reduced forecast, the analyst cut his price targets for names in the Exploration & Production space. Target cuts include Buy-rated Carrizo Oil & Gas (CRZO) to $25 from $32, Buy-rated Continental Resources (CLR) to $42 from $52, Buy-rated Newfield Exploration (NFX) to $40 from $46, Buy-rated Noble Energy (NBL) to $32 from $36, Buy-rated Oasis Petroleum (OAS) to $13 from $16, Buy-rated Pioneer Natural Resources (PXD) to $171 from $192 and Buy-rated Range Resources (RRC) to $36 from $37.
09/08/17
GSCO
09/08/17
DOWNGRADE
Target $20.5
GSCO
Neutral
Range Resources downgraded to Neutral from Buy at Goldman Sachs
Goldman analyst Brian Singer downgraded Range Resources to Neutral and slashed its price target to $20.50 from $35 saying he sees less relative upside in a lower-for-longer gas price environment and notes the company less relative exposure to local Appalachian gas prices.
10/11/17
LEHM
10/11/17
UPGRADE
Target $24
LEHM
Overweight
Range Resources upgraded to Overweight from Underweight at Barclays
Barclays analyst Thomas Driscoll double upgraded Range Resources to Overweight from Underweight and raised his price target for the shares to $24 from $18. The shares are trading at their "most compelling level in years" are declining 50% over the 12 months, Driscoll tells investors in a research note. He expects Range's results will continue to improve in the Marcellus and believes its returns on new capital will meet or exceed peer averages.
09/20/17
WOLF
09/20/17
DOWNGRADE
WOLF
Underperform
Range Resources downgraded to Underperform from Peer Perform at Wolfe Research
Wolfe Research downgraded Range Resources to Underperform largely based on valuation and below average 2018 growth and margins versus peers.
PYPL PayPal
$66.04

-0.19 (-0.29%)

10/06/17
BOFA
10/06/17
NO CHANGE
Target $78
BOFA
Buy
PayPal price target raised to $78 from $71 at BofA/Merrill
BofA/Merrill analyst Jason Kupferberg raised PayPal's Q3 revenue estimate to $3.203B from $3.181B, above the top end of guidance. His Q3 non-GAAP estimate is 44c, in line with consensus and the high end of guidance. Kupferberg continues to believe PayPal is the best positioned company under coverage to capitalize on the global mix shift of payments from offline to online/digital channels. The analyst reiterated his Buy rating ahead of the Q3 report on October 19 and increased his price target to $78 from $71 to reflect a modest increase in 2019 estimates.
10/11/17
MSCO
10/11/17
UPGRADE
MSCO
Overweight
PayPal upgraded to Overweight from Equal Weight at Morgan Stanley
10/11/17
10/11/17
UPGRADE
Target $76

Overweight
PayPal upgraded to Overweight on revised view of eBay risk at Morgan Stanley
As previously reported, Morgan Stanley analyst James Faucette upgraded PayPal (PYPL) to Overweight from Equal Weight, calling it among the few large companies that can deliver high-teens revenue and 20% EPS growth. While he previously was on the sidelines due to risk from its contract renegotiation with eBay (EBAY), he now believes the market may be overly concerned with it as he thinks the most likely renewal structure will feature rebates from PayPal to eBay, he tells investors. Faucette raised his price target on PayPal shares to $76 from $62. He also raised his price target on eBay to $33 from $29, though he keeps an Underweight rating on its shares.
10/10/17
FBCO
10/10/17
NO CHANGE
Target $70
FBCO
Outperform
PayPal price target raised to $70 from $63 at Credit Suisse
Credit Suisse analyst Paul Condra raised his price target for PayPal to $70 from $63 as he continues to like the stock primarily for its pure-play exposure to online/mobile commerce and the potential growth opportunities inherent to this industry. The analyst believes the market underestimates the stickiness of the PayPal platform and expects the brand could gain strength globally as its newly established tech/finance relationships deepen and evolve. He reiterates an Outperform rating on the shares.
JNJ Johnson & Johnson
$135.85

1.945 (1.45%)

10/11/17
JEFF
10/11/17
UPGRADE
Target $157
JEFF
Buy
Johnson & Johnson upgraded to Buy from Hold at Jefferies
Jefferies analyst Jeffrey Holford upgraded Johnson & Johnson to Buy while raising his price target for the shares to $157 from $145. The healthcare giant closed yesterday up 36c to $133.90. J&J's Pharma division is "under-modelled" by analysts and will drive above-consensus revenue and earnings growth, Holford tells investors in a research note. He sees the company's TIRADE pharma assets, or Tremfya, Imbruvica, rivaroxaban, Apalutamide, Darzalex, Esketamine and Stelara, as well as synergies from the Actelion acquisition, driving strong earnings momentum and better than expected dividends. Holford expects J&J shares to re-rate to a 10% market premium.
10/09/17
10/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Larry Biegelsen saying J&J is poised to reaccelerate its sales growth due to accretion from the Actelion acquisition, a "more measured" than expected impact from biosimilar competition, "solid performance" of key drugs and a pipeline that is "coming to fruition." 2. Morgan Stanley (MS) upgraded to Outperform from Neutral at Credit Suisse with analyst Susan Roth Katzke citing the over 10% total return potential in the shares. 3. Disney (DIS) upgraded to Top Pick from Outperform at RBC Capital with analyst Steven Cahall saying he thinks the company has reached a turning point with ESPN approaching less than 20% of earnings and "non-Media" Disney remaining a global leader in content that is executing well. 4. INC Research (INCR) upgraded to Buy from Hold at Jefferies analyst David Windley saying the recent share pullback provides a "compelling" entry point. 5. British American Tobacco (BTI) upgraded to Buy from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/17
10/09/17
NO CHANGE

Valuations in Medical Technology look more attractive, says RBC Capital
RBC Capital analyst Glenn Novarro says the recent pullback in Medical Technology stocks since Q2 earnings has eliminated the valuation gap relative to other S&P Health Care subsectors. The analyst recommends a "Buy Now" for Johnson & Johnson (JNJ) and "Buy on Weakness" for Abbott Laboratories (ABT) among diversified MedTech names. In Cardiovascular, Novarro says "Buy Now" for Edwards Lifesciences (EW) and "Buy on Weakness" for Boston Scientific (BSX). For Nuvasive (NUVA) and Wright Medical (WMGI), the analyst says management will cut guidance because of hurricane related revenue shortfalls, but the selloff over the past several weeks is already discounting those expectations.
10/09/17
WELS
10/09/17
UPGRADE
Target $149
WELS
Outperform
Johnson & Johnson upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Larry Biegelsen upgraded Johnson & Johnson to Outperform and raised his price target for the shares to $149 from $140. The healthcare giant closed Friday up 1c to $133.22. J&J is poised to reaccelerate its sales growth due to accretion from the Actelion acquisition, a "more measured" than expected impact from biosimilar competition, "solid performance" of key drugs and a pipeline that is "coming to fruition," Biegelsen tells investors in a research note. Further, the analyst believes Johnson & Johnson could continue to deliver margin improvement and faster earnings growth.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.